|
Sign In to gain access to subscriptions and/or personal tools.
|
Prevalence and Significance of G6PD Deficiency in Patients of an Urban HIV Clinic
Marisa Tungsiripat*,
Henning Drechsler,
Christine Sarlone,
Kathleen Amyot,
Elizabeth Laffey,
and
Judith Aberg
* To whom correspondence should be addressed. E-mail: tungsim{at}ccf.org.
 |
Abstract |
|---|
The rationale to screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency in HIV-infected individuals is their increased likelihood to receive oxidant drugs and subsequent potential of hemolytic events. However, current guidelines regarding who should be screened are conflicting. The authors examined the prevalence of G6PD deficiency and the frequency of hemolytic events in an urban HIV clinic. They used data from a military database as a comparison. In both cohorts, a relatively high number of black females were found to be G6PD deficient (10% and 13%), which was similar to the rate in men (15% and 12%). No white females were G6PD deficient. The authors identified 8 drug-related hemolytic events in HIV clinic patients. Two patients necessitated blood transfusions; both were triggered by trimethoprim/sulfamethoxazole (TMP/SMX). Although G6PD screening prior to the use of TMP/SMX is not often considered by clinicians, the authors’ finding of 2 hemolytic events requiring transfusion suggests this would be beneficial.
First published on March 18, 2008, doi:10.1177/1545109708315324
Journal of the International Association of Physicians in AIDS Care (JIAPAC) 2008;7:88.
A more recent version of this article appeared on April 1, 2008
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
